COMPARISON THE TREARMENT RESULTS OF TAMSULOSIN AND DOXAZOSIN IN THE MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERTROPHY

Mounzer Alessa*, Hassan Naser and Isaac Mohanna

ABSTRACT

Background: The incidence of LUTS related to benign prostate hyperplasia (BPH) increases to 70% by the age of 80, which seriously affects the quality of life. Moreover these symptoms are associated with substantial personal and social problems. Although there are several options of drugs for treatment the LUTS related to BPH, a1-blockers are still the first-line drugs, and doxazosin and tamsulosin are the most popular ones worldwide. Objective: This study aims to evaluate the effectiveness and the safety of the tamsulosin and doxazosin in management of lower urinary tract symptoms associated with benign prostatic hypertrophy, and determine which one is more effective than the other. Methods and materials: Patients aged between 50-80 years and diagnosed with benign prostate hyperplasia (BPH) with International Prostatic Symptom Score (IPSS) total symptom score >8 were included. A total of 100 patients were randomized to treatment with 4mg of doxazosin daily (n = 50) or 0.4 mg of tamsulosin daily (n = 50) for 12 weeks. Efficacy was assessed at 0 weeks,6 weeks and 12 weeks of treatment ,using total IPSS, storage subscore and voiding subscore to determine changes in LUTS and urinary flow rates. Adverse events (AE) were recorded at each visit based on patient reports. QOL was assessed by the ‘quality of life due to urinary symptoms’ question from the IPSS questionnaire. Results: The total IPSS, voiding IPSS and storage IPSS each had decreased significantly after 12 weeks of treatment in the doxazosin group (P<0.05). However, only the T-IPSS had decreased significantly after 12 weeks of treatment in the tamsulosin group (P<0.05),while the decrease occurred in V-IPSS and S- IPSS in the tamsulosin group had no significance (P>0.05). However the improvement occurred in the QOL was significant in either the doxazosin and tamsulosin groups (P<0.05). Conclusion: Our results show superior efficacy of doxazosin over tamsulosin in terms of S-IPSSS and V- IPSS. Thus, doxazosin is superior to tamsulosin in the management of LUTS in patients with BPH.

Keywords: Doxazosin, Tamsulosin, BPH, IPSS.